‘Wild West’: Cancer Drug Advances Are Creating Data Gaps Sarah Amandolare

https://www.medscape.com/viewarticle/wild-west-cancer-drug-advances-are-creating-data-gaps-2026a1001104 In 2020, pembrolizumab became a first-line treatment for certain patients with metastatic colorectal cancer (CRC). The FDA approval essentially moved pembrolizumab from a later-line option to the frontline setting, marking an important change for patients with microsatellite instability-high or mismatch repair-deficient disease.